AstraZeneca and the Stroke Alliance for Europe (SAFE) today announced the
launch of the world's most comprehensive Global Stroke Survey. The research
project, revealed at the European Stroke Conference (ESC) meeting, will assess
the true burden of stroke for patients and caregivers, with the first results
expected in late 2006.
Arne Hagen, President of the Stroke Alliance for Europe (SAFE) said, 'We
are excited to be partnering with AstraZeneca on this important initiative. The
need for education about stroke and stroke prevention is overwhelming --
fifteen million people worldwide suffer a stroke each year. One in three of
these people die, a further third are left with varying degrees of disability,
and only one third of stroke victims recover without disability (1). Stroke is
a life-shattering event, yet very few people can recognise the symptoms or
understand the devastating impact stroke can have on patients and families. We
look forward to the results of this Global Stroke Survey.'
The Global Stroke Survey will be designed to provide in-depth understanding
of the true burden, social consequences, and functional and emotional distress
caused by stroke around the world. Variations between countries will also be
investigated to build a comparative picture of standards in stroke care across
Dr. Tomas Odergren, Vice President, Global Product Director, Development at
AstraZeneca, commented: 'Stroke is a medical emergency with potentially
devastating consequences if treatment is not sought immediately. Yet poor
understanding of the symptoms of stroke often means diagnosis and treatment is
delayed. Our hope is that results from this Global Stroke Survey initiative
will deepen our understanding of the burden of stroke and contribute to better
outcomes for stroke patients in the future.'
The survey will be conducted in France, Germany, Italy, Spain, UK, Sweden,
Australia, China, Canada and the USA. Its reach will be extensive; a total of
2,400 patients and 2,400 caregivers will be surveyed following recruitment
through medical professionals. A steering committee, consisting of patient
organisations like SAFE and leading stroke experts will guide the development
of the survey.
AstraZeneca has a firm commitment to stroke research and awareness, and
continues to support scientists, physicians, and patients with the aim of
improving stroke treatment.
Source: PTI News